CD11c+ DCs in peripheral blood can activate toll-like receptor 7 (TLR7) to trigger the production of ROS, driving the TLR7/mROS/IL-12 axis to enhance the tumor-killing ability of NK cells 116. Here, TLR7 is linked to neoplasm.